Rx (Prescription Medicine)
USD $ 117.00
Dasatib 50mg Tablet是一种靶向治疗药物，用于治疗某些类型的癌症，主要包括慢性髓系白血病（CML）和费城染色体阳性急性淋巴细胞白血病（Ph+ ALL）。其活性成分Dasatinib是一种酪氨酸激酶抑制剂（TKI）。它通过阻断特定酶（酪氨酸激酶）的活性，这些酶参与癌细胞的生长和增殖。通过抑制这些酶，Dasatib有助于减缓或停止癌性肿瘤的生长，并可导致癌细胞数量下降。该药物通常由合格的肿瘤科医生处方，剂量取决于具体的癌症类型和阶段、患者的个体反应以及耐受性。常见的不良反应可能包括腹泻、恶心、皮疹、疲劳、头痛、肌肉疼痛以及体液潴留。与您的医疗提供者讨论任何潜在的不良反应非常重要。Dasatib 50mg Tablets应储存在室温下，避免潮湿和热源，并放在儿童不易触及的地方。
| Molecule | |
|---|---|
| Strength | |
| Pack Quantity | |
| Medicine Form | |
| Medicine Type | |
| Rx Status | |
| Country Of Origin | |
| Packaging Type | |
| Brand Name |
其他品牌的 Dasatinib 50 Mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
